1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Xbrane Welcomes Milestone In $14bn Nivolumab Journey, Partner Sought

Potential For Clinical Trials In H1 2025; Commercialization Deal Due Later This Year

 
• By Dean Rudge

In a for-now limited pool of chasers, Sweden’s Xbrane Biopharma has unveiled a milestone and business update for its proposed biosimilar to Bristol Myers Squibb’s major PD-1 inhibitor, Opdivo.

Asphalt road with arrow guideline and Milestone letters painted on the surface. An image of a road milestones are representative of success in the future goal. Road to success with light of the sun
• Source: Shutterstock

Manufacturing for Xbrane Biopharma’s proposed biosimilar to Bristol Myers Squibb’s Opdivo (nivolumab) is now taking place at the scale required for future commercialization and clinical trials, the Swedish firm has revealed, as it laid out plans to wrap up a partnership for its proposed immuno-oncology PD-1 inhibitor biosimilar, Xdivane, later this year.

Xbrane says its achievement is the result of an investment set to reach $25m by the end of 2024, putting it on a path to produce nivolumab clinical material this year and move forward

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Sandoz Slims Down Pembrolizumab Trial As Regulators Streamline Requirements

 
• By Dave Wallace

As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.

Amgen’s Aflibercept Starts Strong As Regeneron Counts Cost Of Eylea Competition

 
• By Dean Rudge

Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

More from Products

J&J Denied Injunction Over Private-Label Ustekinumab In US

 
• By Dave Wallace

Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

What’s Next? Five Things To Look Out For In May

 
• By Dean Rudge

Generics Bulletin previews the most noteworthy and anticipated events for May 2025.